ストックスクリーナーアプリを入手
30.44
2.63%
0.78
アフターアワーズ：
29.84
-0.60
-1.97%
前日終値:
$29.66
開ける：
$29.545
24時間の取引高:
1.09M
Relative Volume:
0.87
時価総額：
$3.22B
収益：
-
当期純損益:
$-150.70M
株価収益率:
-19.64
EPS:
-1.55
ネットキャッシュフロー:
$-125.67M
1週間 パフォーマンス:
+3.86%
1か月 パフォーマンス:
+3.68%
6か月 パフォーマンス:
+110.66%
1年 パフォーマンス:
+15.35%
1日の値動き範囲:
$29.36
$30.46
1週間の範囲:
$28.98
$31.82
52週間の値動き範囲:
$10.60
$31.82
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
Compare EWTX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
30.44 | 3.14B | 0 | -150.70M | -125.67M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.83 | 121.97B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
781.67 | 81.49B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
766.92 | 47.74B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
332.92 | 43.93B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
316.99 | 35.67B | 4.98B | 69.60M | 525.67M | 0.5198 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-25 | 開始されました | Goldman | Neutral |
| 2025-07-30 | 開始されました | Raymond James | Strong Buy |
| 2025-06-30 | 開始されました | H.C. Wainwright | Buy |
| 2025-04-30 | 開始されました | Guggenheim | Buy |
| 2025-04-02 | ダウングレード | Scotiabank | Sector Outperform → Sector Perform |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2025-01-22 | 開始されました | Stifel | Hold |
| 2024-11-22 | 開始されました | Evercore ISI | Outperform |
| 2024-03-07 | 開始されました | Piper Sandler | Overweight |
| 2023-05-01 | 開始されました | Truist | Buy |
| 2022-08-25 | ダウングレード | Goldman | Neutral → Sell |
| 2022-04-13 | 開始されました | RBC Capital Mkts | Outperform |
| 2022-01-28 | 開始されました | Goldman | Neutral |
すべてを表示
Edgewise Therapeutics Inc (EWTX) 最新ニュース
Stifel raises Edgewise Therapeutics stock price target on trial data timeline - Investing.com Canada
Edgewise Therapeutics, Inc. SEC 10-K Report - TradingView
Assessing Edgewise Therapeutics (EWTX) Valuation After Strong Multi‑Year Returns And Recent Share Price Momentum - Yahoo Finance
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs - PR Newswire
Edgewise Therapeutics (NASDAQ:EWTX) Reaches New 52-Week HighStill a Buy? - MarketBeat
Edgewise Therapeutics stock hits 52-week high at $31.39 - Investing.com
Edgewise Therapeutics, Inc. (EWTX) Stock Analysis: Target Price Suggests 26.84% Upside for Biotech Innovator - DirectorsTalk Interviews
How Edgewise Therapeutics Inc. (EWTX) Affects Rotational Strategy Timing - Stock Traders Daily
Edgewise Therapeutics (EWTX) Projected to Post Earnings on Monday - MarketBeat
Published on: 2026-02-21 16:05:11 - mfd.ru
Aberdeen Group plc Has $10.05 Million Holdings in Edgewise Therapeutics, Inc. $EWTX - MarketBeat
Forecast Cut: Will Edgewise Therapeutics Inc benefit from current market trendsJuly 2025 PostEarnings & Weekly Breakout Watchlists - baoquankhu1.vn
Aug Summary: Is FLIC on track to beat earningsWeekly Profit Recap & Step-by-Step Trade Execution Guides - baoquankhu1.vn
Edgewise Therapeutics earnings on deck as pipeline advances By Investing.com - Investing.com South Africa
Edgewise Therapeutics earnings on deck as pipeline advances - Investing.com Nigeria
Edgewise Therapeutics, Inc. (EWTX) Stock Analysis: A High-Potential Biotech Play with 27% Upside - DirectorsTalk Interviews
GSA Capital Partners LLP Increases Holdings in Edgewise Therapeutics, Inc. $EWTX - MarketBeat
Published on: 2026-02-16 03:13:40 - mfd.ru
Is Edgewise Therapeutics Inc. gaining market shareJuly 2025 Reactions & Community Trade Idea Sharing Platform - mfd.ru
What is Edgewise Therapeutics Inc.’s book value per share2025 Fundamental Recap & Reliable Entry Point Trade Alerts - mfd.ru
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Upgraded at Wall Street Zen - MarketBeat
Will Edgewise Therapeutics Inc. stock gain from government policies2025 Fundamental Recap & Reliable Entry Point Trade Alerts - mfd.ru
Edgewise Therapeutics Teases Phase 3 Sevasemten Readout, HCM Data Update at Guggenheim Conference - MarketBeat
(EWTX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Is Edgewise Therapeutics Inc. stock positioned for long term growthJuly 2025 Review & Low Risk High Reward Trade Ideas - mfd.ru
EWTX: Phase III readouts and new cardiac programs drive momentum, with strong commercial readiness - TradingView
Can Edgewise Therapeutics Inc. reach all time highs this yearJuly 2025 Rallies & Free Accurate Trade Setup Notifications - mfd.ru
Assessing Edgewise Therapeutics (EWTX) Valuation After Recent Share Price Momentum - Yahoo Finance
Edgewise Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026 - PR Newswire
Is Edgewise Therapeutics Inc. subject to activist investor interestJuly 2025 WrapUp & Low Drawdown Trading Techniques - mfd.ru
Why Edgewise Therapeutics Inc. stock remains on watchlistsSwing Trade & Daily Technical Forecast Reports - mfd.ru
Piper Sandler Sticks to Their Buy Rating for Edgewise Therapeutics (EWTX) - The Globe and Mail
Why Edgewise Therapeutics stock crushed the market on Monday - MSN
Edgewise Therapeutics stock hits 52-week high at $30.26 By Investing.com - Investing.com South Africa
Analyst Reiterates Bullish Stance on Edgewise Stock - Intellectia AI
Why Edgewise Therapeutics Stock Crushed the Market on Monday - AOL.com
Edgewise Therapeutics (NASDAQ:EWTX) Sets New 12-Month HighTime to Buy? - MarketBeat
Why Edgewise Therapeutics Stock Crushed the Market on Monday - The Motley Fool
Edgewise Therapeutics stock hits 52-week high at $30.26 - Investing.com Nigeria
Piper Sandler reiterates Overweight rating on Edgewise Therapeutics stock By Investing.com - Investing.com Canada
Piper Sandler reiterates Overweight rating on Edgewise Therapeutics stock - Investing.com
Federated Hermes Inc. Decreases Stock Holdings in Edgewise Therapeutics, Inc. $EWTX - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Downgraded by Wall Street Zen to Sell - MarketBeat
Growth Recap: Can Edgewise Therapeutics Inc expand its profit margins2025 Earnings Impact & Weekly Stock Breakout Alerts - baoquankhu1.vn
Braveheart Bio names Marc Evanchik CSO - The Pharma Letter
Hot Picks: Biotech rebound turns to rare disease catalysts - BNN Bloomberg
Why Edgewise Therapeutics Inc. stock remains undervaluedEarnings Recap Report & Reliable Volume Spike Alerts - mfd.ru
Edgewise Therapeutics (EWTX): Analyst Consensus Reveals A 32% Upside Potential - DirectorsTalk Interviews
Dow Update: What analysts say about Edgewise Therapeutics Inc stockJuly 2025 Review & AI Enhanced Execution Alerts - baoquankhu1.vn
Edgewise Therapeutics Inc (EWTX) 財務データ
収益
当期純利益
現金流量
EPS
Edgewise Therapeutics Inc (EWTX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Edris Badreddin | Director |
Jan 21 '26 |
Sale |
29.44 |
115,471 |
3,399,466 |
19,820 |
1.18%
0.45%
大文字化:
|
ボリューム (24 時間):